CA3187754A1 - Cleavable linker compositions and methods - Google Patents

Cleavable linker compositions and methods

Info

Publication number
CA3187754A1
CA3187754A1 CA3187754A CA3187754A CA3187754A1 CA 3187754 A1 CA3187754 A1 CA 3187754A1 CA 3187754 A CA3187754 A CA 3187754A CA 3187754 A CA3187754 A CA 3187754A CA 3187754 A1 CA3187754 A1 CA 3187754A1
Authority
CA
Canada
Prior art keywords
isolated polypeptide
cytokine
polypeptide
receptor
cleavable linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187754A
Other languages
English (en)
French (fr)
Inventor
David Campbell
Thomas R. DIRAIMONDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janux Therapeutics Inc
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of CA3187754A1 publication Critical patent/CA3187754A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3187754A 2020-08-11 2021-08-10 Cleavable linker compositions and methods Pending CA3187754A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064268P 2020-08-11 2020-08-11
US63/064,268 2020-08-11
PCT/US2021/045395 WO2022035866A1 (en) 2020-08-11 2021-08-10 Cleavable linker compositions and methods

Publications (1)

Publication Number Publication Date
CA3187754A1 true CA3187754A1 (en) 2022-02-17

Family

ID=80223911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187754A Pending CA3187754A1 (en) 2020-08-11 2021-08-10 Cleavable linker compositions and methods

Country Status (10)

Country Link
US (3) US11512113B2 (cg-RX-API-DMAC7.html)
EP (2) EP4196488B1 (cg-RX-API-DMAC7.html)
JP (2) JP7681681B2 (cg-RX-API-DMAC7.html)
KR (2) KR102944047B1 (cg-RX-API-DMAC7.html)
CN (1) CN116348597A (cg-RX-API-DMAC7.html)
AU (2) AU2021326469C1 (cg-RX-API-DMAC7.html)
CA (1) CA3187754A1 (cg-RX-API-DMAC7.html)
ES (1) ES3040950T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023001788A (cg-RX-API-DMAC7.html)
WO (1) WO2022035866A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111247171A (zh) * 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US12534734B2 (en) * 2018-05-15 2026-01-27 Drive Therapeutics Llc Stem-loop compositions and methods for inhibiting interleukin-8
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
KR20250024874A (ko) * 2022-04-04 2025-02-19 재눅스 테라퓨틱스 인크. Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법
WO2024100451A2 (en) * 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN122349537A (zh) 2023-12-01 2026-07-07 阿布林克斯有限公司 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
WO2025201560A1 (en) * 2024-03-29 2025-10-02 Vibrant Pharma Limited Multispecific antigen-binding proteins and uses thereof
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US20010031264A1 (en) 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗egfr抗体の凍結乾燥製剤
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016077505A2 (en) * 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
AU2017364818C1 (en) * 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
JP2022512124A (ja) * 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
US20230220105A1 (en) 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods

Also Published As

Publication number Publication date
EP4196488A4 (en) 2024-08-07
ES3040950T3 (en) 2025-11-06
EP4631977A3 (en) 2025-12-10
US20230147782A1 (en) 2023-05-11
WO2022035866A1 (en) 2022-02-17
KR20230080399A (ko) 2023-06-07
AU2021326469A1 (en) 2023-04-06
MX2023001788A (es) 2023-04-26
US20250019403A1 (en) 2025-01-16
KR102944047B1 (ko) 2026-03-26
CN116348597A (zh) 2023-06-27
US20220048949A1 (en) 2022-02-17
AU2021326469B2 (en) 2025-11-20
JP2025131591A (ja) 2025-09-09
EP4196488C0 (en) 2025-08-06
AU2021326469C1 (en) 2026-04-30
KR20260042619A (ko) 2026-03-31
JP7681681B2 (ja) 2025-05-22
EP4631977A2 (en) 2025-10-15
EP4196488B1 (en) 2025-08-06
JP2023547978A (ja) 2023-11-15
US11512113B2 (en) 2022-11-29
AU2026200907A1 (en) 2026-02-26
EP4196488A1 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
US11512113B2 (en) Cleavable linker compositions and methods
EP3820569B1 (en) Antibody molecules that bind pd-l1 and cd137
EP3013859B1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
US20230348618A1 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
EP4259202A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
EP4337794A1 (en) Antibodies targeting egfr and cd3 and uses thereof
US8822649B2 (en) Anti-CLTA4, anti-GLUT2 protein for the treatment of type 1 diabetes
WO2025097043A1 (en) Antibodies for targeting psma and cd28 and uses thereof
HK40109153A (en) Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250801

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250801

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250813

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251007

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251007

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251007

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260731